MPO and cancer: The importance of murine neutrophil MPO has been shown using a novel tripeptide MPO inhibitor [N-acetyl lysyltyrosylcysteine amide (KYC)], which diminished lung tumor burden, suggesting that targeting neutrophil MPO is a novel cancer treatment (199).